a take from Derek Lowe on AI drugs: https://www.science.org/content/blog-post/ai-drugs-so-far
They began with a list of AI-focused companies (114!), then matched that up with the clinical projects that are reported for them (39 of them).
If you look at the 2023 figures, the authors have 24 AI-discovered targets, 22 AI-optimized small molecules, 4 antibodies, 6 vaccines, and 10 repurposed compounds. So what do we think about those figures?
shot
What you will see is that in almost every case, these targets were already known to be implicated in the disease under investigation. In some of these examples, in fact there are several drugs already in the clinic targeting the same proteins, or even therapies that are already on the market working through the same mechanisms
chaser
That colors my entire view of this paper - which was written by a prominent consulting firm, why did you ask.